NCT00351585View on ClinicalTrials.gov

A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Vildagliptin

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00351585 - A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter